BURLINGTON, ON, June 6 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") TSX Venture Exchange: JEN, Frankfurt: JNX) announced today, in
accordance with press releases dated March 9, 2007 and May 25, 2007, they have
completed the transactions to issue 148,148 common shares and 219,994 common
shares, respectively, at a deemed price of 27 cents per common share to
extinguish a total $99,398.48 in trade payables. The TSX Venture Exchange has
approved this transaction. The shares are subject to the customary four month
hold period from date of issue.
About The Jenex Corporation
The Jenex Corporation owns a patented Thermal Therapy technology. The
first device developed from this technology is the Therapik(R) product, for
relief of pain and itch caused by insect stings and bites. Therapik(R) has
been approved as a Class II medical device in Canada (TPD) and the United
States (FDA), and has received CE approval in Europe. The second device,
interceptCS is the first product clinically proven and approved (TPD) to
prevent cold sores. interceptCS is available exclusively in Canada at Shoppers
Drug Mart/Pharmaprix. More information about the Corporation can be found at
www.jenexcorp.com and www.interceptCS.com.
"Prevention is the Solution"
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release.
For further information:
For further information: Direct Inquiries to: The Jenex Corporation, 207
- 940 Sheldon Court, Burlington, Ontario, L7L 5K6, Michael A. Jenkins,
Telephone: (905) 632-3830, Facsimile: (905) 632-3774, Email:
email@example.com, Website: www.jenexcorp.com